biostudies-literatureKim HKKorean Society of Surgical Oncologyzraf168https://www.ebi.ac.uk/biostudies/studies/S-EPMC12911035biostudies-literatureUnknown10(1)<h4>Background</h4>Nipple-sparing mastectomy (NSM) is a surgical option offering both oncological safety and cosmetic benefits. However, the oncological safety of NSM in carriers of BRCA1/2 pathogenic variants/likely pathogenic variants (PV/LPV) with breast cancer and the role of risk-reducing mastectomy remain underexplored, especially in Asian populations. This study evaluated the safety and effectiveness of NSM in BRCA1/2 PV/LPV carriers and assessed the preventive impact of contralateral risk-reducing NSM (RRNSM) on cancer incidence.<h4>Methods</h4>This multicentre retrospective study included women aged 20-80 years who underwent NSM for therapeutic or risk-reducing purposes and received germline BRCA1/2 tests between May 2006 and June 2022 across 19 institutions in Korea. Patients witBJS openOncological safety and preventive impact of nipple-sparing mastectomy in patients with BRCA1/2 mutation: multicentre study of the Korea Robot-endoscopy Minimal Access Breast Surgery Study Group (KoREa-BSG).PMC12911035KSSO-21-05Kim DShin DSLee JEKim YYBae SYLee JKim KSLee ESPark HSKorea Robot-endoscopy Minimal Access Breast Surgery Study Group (KoREa-BSG)Chang YWKang YJShin HCChoi JENam SEKim MKLee JHShin HJKim HKLee MHKwon SUJang SYChoi HJLee HYLee SBYe Kim JKim EYKim SMin JBae SJChoi YJRyu JMKim JHKim ZKo BSCha CDHan SAPark EfalseOncological safety and preventive impact of nipple-sparing mastectomy in patients with BRCA1/2 mutation: multicentre study of the Korea Robot-endoscopy Minimal Access Breast Surgery Study Group (KoREa-BSG).<h4>Background</h4>Nipple-sparing mastectomy (NSM) is a surgical option offering both oncological safety and cosmetic benefits. However, the oncological safety of NSM in carriers of BRCA1/2 pathogenic variants/likely pathogenic variants (PV/LPV) with breast cancer and the role of risk-reducing mastectomy remain underexplored, especially in Asian populations. This study evaluated the safety and effectiveness of NSM in BRCA1/2 PV/LPV carriers and assessed the preventive impact of contralateral risk-reducing NSM (RRNSM) on cancer incidence.<h4>Methods</h4>This multicentre retrospective study included women aged 20-80 years who underwent NSM for therapeutic or risk-reducing purposes and received germline BRCA1/2 tests between May 2006 and June 2022 across 19 institutions in Korea. Patients wit2025-01-01T00:00:00Z2025 Dec2026-07-16T04:59:06.638Z2026-07-09T13:10:05.363ZS-EPMC129110354170121910.1093/bjsopen/zraf168